Cost-effectiveness of dialysis and kidney transplantation to treat end-stage renal disease in Ukraine.

Q4 Medicine
Serhii M Hryshchuk, Valentin D Parii
{"title":"Cost-effectiveness of dialysis and kidney transplantation to treat end-stage renal disease in Ukraine.","authors":"Serhii M Hryshchuk, Valentin D Parii","doi":"10.36740/WLek202404123","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Aim: To determine the economic feasibility of using kidney transplantation compared to hemodialysis in end-stage renal disease in the long term in countries with a low and medium level of economic development using the example of Ukraine.</p><p><strong>Patients and methods: </strong>Materials and Methods: The cost effectiveness analysis method was used. Conducted Markov modeling and comparison of the consequences of kidney transplantation and hemodialysis in terms of treatment costs and the number of added years of life for a cohort of 1,675 patients were carried out. The incremental cost-effectiveness ratio is defined.</p><p><strong>Results: </strong>Results: Based on the results of modeling, it was determined that among 1,675 patients with end-stage kidney disease in Ukraine, 1,248 (74.5%) will remain alive after 10 years of treatment when kidney transplantation technology is used. The highest costs will be in the first year ($25,864), and in subsequent years - about $5,769. With the use of hemodialysis technology, only 728 patients (43.5%) will be alive after 10 years, the cost of treating one patient per year is $11,351. The use of kidney transplantation adds 3191 years of quality life for 1675 patients compared with hemodialysis (1.9 years per patient).</p><p><strong>Conclusion: </strong>Conclusions: Kidney transplantation is an economically feasible technology for Ukraine, as the incremental cost-effectiveness ratio is $4694, which is 1.04 times higher than Ukraine's GDP per capita. The results of the study allow us to recommend that decision-makers in countries with a low and medium level of economic development give priority in financing to renal transplantation.</p>","PeriodicalId":23643,"journal":{"name":"Wiadomosci lekarskie","volume":"77 4","pages":"765-771"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiadomosci lekarskie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36740/WLek202404123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Aim: To determine the economic feasibility of using kidney transplantation compared to hemodialysis in end-stage renal disease in the long term in countries with a low and medium level of economic development using the example of Ukraine.

Patients and methods: Materials and Methods: The cost effectiveness analysis method was used. Conducted Markov modeling and comparison of the consequences of kidney transplantation and hemodialysis in terms of treatment costs and the number of added years of life for a cohort of 1,675 patients were carried out. The incremental cost-effectiveness ratio is defined.

Results: Results: Based on the results of modeling, it was determined that among 1,675 patients with end-stage kidney disease in Ukraine, 1,248 (74.5%) will remain alive after 10 years of treatment when kidney transplantation technology is used. The highest costs will be in the first year ($25,864), and in subsequent years - about $5,769. With the use of hemodialysis technology, only 728 patients (43.5%) will be alive after 10 years, the cost of treating one patient per year is $11,351. The use of kidney transplantation adds 3191 years of quality life for 1675 patients compared with hemodialysis (1.9 years per patient).

Conclusion: Conclusions: Kidney transplantation is an economically feasible technology for Ukraine, as the incremental cost-effectiveness ratio is $4694, which is 1.04 times higher than Ukraine's GDP per capita. The results of the study allow us to recommend that decision-makers in countries with a low and medium level of economic development give priority in financing to renal transplantation.

乌克兰透析和肾移植治疗终末期肾病的成本效益。
目的目的:以乌克兰为例,确定在中低经济发展水平的国家,与血液透析相比,在终末期肾病患者中长期使用肾移植的经济可行性:材料和方法:采用成本效益分析方法。对 1675 名患者进行了马尔可夫模型分析,并比较了肾移植和血液透析在治疗费用和增加寿命年数方面的后果。界定了增量成本效益比:结果:结果:根据建模结果确定,在乌克兰的 1,675 名终末期肾病患者中,如果采用肾移植技术,1,248 人(74.5%)在治疗 10 年后仍可存活。第一年的费用最高(25 864 美元),随后几年的费用约为 5 769 美元。如果使用血液透析技术,10 年后只有 728 名病人(43.5%)存活,每年治疗一名病人的费用为 11 351 美元。与血液透析相比,使用肾移植技术可为 1675 名患者增加 3191 年的高质量生活(每名患者增加 1.9 年):结论:结论:对乌克兰而言,肾移植是一项经济上可行的技术,因为其增量成本效益比为 4694 美元,是乌克兰人均 GDP 的 1.04 倍。根据研究结果,我们建议中低经济发展水平国家的决策者优先考虑为肾移植提供资金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Wiadomosci lekarskie
Wiadomosci lekarskie Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
482
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信